FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia
Launched by DASMAN DIABETES INSTITUTE · Oct 30, 2019
Trial Information
Current as of April 27, 2025
Withdrawn
Keywords
ClinConnect Summary
Study design:
Open-label, crossover, single center, randomized controlled trial of FreeStyle Libre with MiaoMiao Bluetooth transmitter adjunct with calibrations (FSL-M) compared to FreeStyle Libre alone (FSL-A) in people with T1DM.
Protocol summary:
Following informed written consent, subjects will be randomized to either FSL-M group using FSL with Miaomio and Tomato App premium version, or FSL-A with Libre Link app (stage 1). Subjects will spend 8 weeks in the assigned group followed by 2 weeks washout then subjects will switch over to the other group for further 8 weeks (stage 2).
Whi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. T1DM for 12 months or more
- • 2. Age \>21 years old
- • 3. Established user of FreeStyle Libre for ≥3 months
- • 4. HbA1C \<12% (108mmol/mol)
- • 5. Able to check glucose with finger prick several times a day
- Exclusion Criteria:
- • 1. Pregnancy or plans for pregnancy over the duration of the study
- • 2. Breast feeding
- • 3. Renal impairment with eGFR \<30ml/minute/1.73m2
- • 4. Significant anaemia (males Hb\<110g/L, females Hb \<100g/L)
- • 5. Active malignancy
- • 6. Significant vision impairment
- • 7. Any significant illness- decision will be made by the PI or Co-I
- • 8. Not able to attend study visits
- • 9. Not able or not willing to participate in all study components
- • 10. Not able or not willing to give written informed consent
About Dasman Diabetes Institute
Dasman Diabetes Institute (DDI) is a leading research and clinical organization dedicated to advancing diabetes care and management through innovative research, education, and community outreach. Established to address the growing prevalence of diabetes, DDI focuses on conducting high-quality clinical trials aimed at developing effective prevention and treatment strategies. The institute collaborates with local and international partners to enhance understanding of diabetes and its complications, fostering a multidisciplinary approach that integrates clinical practice with cutting-edge research. With a commitment to improving patient outcomes, DDI serves as a vital resource for healthcare professionals, researchers, and individuals affected by diabetes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kuwait City, , Kuwait
Patients applied
Trial Officials
Ali Aldibbiat, MD PhD FRCP
Principal Investigator
Dasman Diabetes Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials